Drug Profile
BZF 961
Alternative Names: BZF961Latest Information Update: 19 Feb 2016
Price :
$50
*
At a glance
- Originator Novartis
- Class Antivirals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 18 Feb 2016 Discontinued - Phase-I/II for Hepatitis C in USA (unspecified route)
- 31 Mar 2013 Phase-I/II clinical trials in Hepatitis C in USA (unspecified route)